Zymeworks Inc. (ZYME)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
28.59+1.97 (+7.40%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 26.62 |
| Open | 26.83 |
| Bid | 19.00 x 900 |
| Ask | 33.00 x 800 |
| Day's Range | 26.71 - 29.06 |
| 52 Week Range | 24.82 - 59.03 |
| Volume | 359,497 |
| Avg. Volume | 440,104 |
| Market Cap | 1.32B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.80 |
| Earnings Date | Aug 03, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.46 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Business Wire
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021 (the "Meeting").
- Zacks
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Zymeworks Reports 2021 First Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021.
© 2021 Verizon Media. All rights reserved.
